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It is a distinct pleasure for me to introduce Sir David
Weatherall, the recipient of the 2003WilliamAllanAward
of the American Society of Human Genetics. This award
is the highest honor that the Society can bestow upon
a scientist for contributions to human genetics. As one
who has followed his career over the past 40 years, I
ﬁrmly believe that this honor is well deserved and long
overdue.
David Weatherall graduated from the Medical School
at the University of Liverpool in 1956. After house staff
training, he joined the Army for a 2-year assignment that
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would chart the future course of his career. Returning
frommilitary service, he took a fellowship at JohnsHop-
kins before returning to Liverpool, where he rose to the
rank of professor. In 1974, he was appointed Nufﬁeld
Professor of Clinical Medicine at the University of Ox-
ford, and, in 1992, he assumed the most prestigious chair,
of Regis Professor of Medicine. In 1989, he founded the
Institute of Molecular Medicine at Oxford, which was
renamed the Weatherall Institute of Molecular Medicine
in his honor, in the year 2000 (ﬁg. 1).
David’s contributions to genetic disorders and thalas-
semia are legend. However, it is interesting to note from
his own reﬂection how he came to enter this ﬁeld (Weath-
erall 2001). Two years after he qualiﬁed in medicine, he
was called to serve his country, and he joined the Royal
Army Medical Corps as part of his compulsory service.
Having an aversion to ﬂying, bullets, and snakes, he vol-
unteered to serve in the United Kingdom. The army, in
its inﬁnite wisdom, shipped him to Singapore instead.
And in another stroke of genius, the army put him in
charge of a children’s ward at the British Military Hos-
pital (ﬁg. 2), even though he had no pediatrics training.
One of his ﬁrst patients was a Gurkha child from Nepal
who had a mysterious illness that required regular blood
transfusions to keep her alive. With his biochemist col-
league Frank Vella in Singapore, he performed hemoglo-
bin electrophoresis on the child’s parents and discovered
that they had increased HbA2. Brilliantly, they made the
diagnosis of homozygous b thalassemia, no mean task
in those early days. Triumphantly, they published their
breakthrough ﬁndings in the British Medical Journal,
(Weatherall and Vella 1960), whereupon they were im-
mediately called on the carpet by the Director General
of Medical Services for the Far Eastern Forces. He was
told that he could be court-martialed for publishing in-
formation about military personnel without permission
from the War Ofﬁce, and, in any case, it was bad form
to reveal to the world that one of the personnel from
the Gurkha regiments had bad genes. He was ordered
not to do it again. Perhaps it was because of this rep-
rimand and David’s deﬁant nature that he decided to
spend his life pursuing bad genes, and he has not stopped
ever since.
After the stint in Singapore, he spent a fellowship in
the Johns Hopkins Hospital under the tutelage of two
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giants in genetics and hematology, Victor McKusick and
C. Lockhard Conley (ﬁg. 3). His achievements since then
have been so overwhelming and far reaching that I can
only touch on a few highlights.
With the late Hermann Lehmann, he studied the hu-
man hemoglobin variants and described a number of
novel hemoglobins, including those that cause methemo-
globinemia and polycythemia. In the 1960s, David re-
turned to the study of the genetic and molecular basis of
thalassemia.With John Clegg (ﬁg. 4), he devised amethod
that accurately measured the synthesis of the a- and b-
globin chain in patients with various thalassemia syn-
dromes (Weatherall et al. 1965). On a personal note, it
was the sheer elegance of this measurement that at-
tracted me to begin my own studies in thalassemia. He
described or clariﬁed many other thalassemia syndromes,
such as HbConstantSpring, hereditary persistence of fetal he-
moglobin, and db thalassemia (Milner et al. 1971). With
the advent of molecular biology, he moved with Robert
Williamson’s group to the studies of the genes and gene
expression in these syndromes and described the deletion
of the a-globin genes in a thalassemia and gene deletion
in db thalassemia, among other molecular defects in thal-
assemia (Ottolenghi et al. 1974, 1976). He correlated
the genotype-phenotype relationship of the various thal-
assemia syndromes. Also, he described novel cases of
mental retardation associated with a thalassemia that re-
sult from the deletion of a large segment of chromosome
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16 or from a mutation in the X chromosome that affects
the expression of the a-globin gene (Wilkie et al. 1990a,
1990b). His studies in thalassemia bridged the clinical as-
pects of the diseases to theirmolecular basis and constitute
the model for our studies of many genetic diseases.
In recent years, David turned his work to the HbE
syndromes and their interactions with b thalassemia, an
important disease entity in regions in Southeast Asia, such
as Thailand and Sri Lanka (de Silva et al. 2000). He
spends a great deal of time and effort in these areas,
where, in Sri Lanka, he helped launch a clinic for the
studies of these syndromes.
The accolades that David has received during his dis-
tinguished career are far too numerous to name here.
Among his honors are many named lectures, some 24
honorary degrees, and 26 international prizes. He is a
member of many international learned societies—for in-
stance, he is a Fellow of the Royal Society and a foreign
member of the National Academy of Sciences and the
Institute of Medicine. For his contributions, he was
knighted by the Queen in 1987.
David has trained a large number of research leaders
around the world. Moreover, he educates a global au-
dience through his tireless writings that include reviews,
chapters, and original papers numbering almost 600. He
haswritten and edited 14 books—ranging from textbooks
of medicine and hematology, genetic engineering, and his-
tory of medicine—several of which have gone through
multiple editions. Of course, his book, The Thalassemia
Syndromes, now in its fourth edition, is the Bible, which
everyone in the ﬁeld must read.
Members of the American Society of HumanGenetics,
it gives me great pleasure to present to you Sir David
Weatherall.
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